Source: Irene M. Kang, MD, of City of Hope Comprehensive Cancer Center in Irvine, California, From: medscape.com TOPLINE: In a prespecified secondary analysis of the RxPONDER trial, chemoendocrine therapy was associated with larger and more sustained declines in patient-reported cognitive function than endocrine therapy alone in both pre- and postmenopausal patients with hormone receptor-positive ERBB2-negative breast cancer over a period …
Chemotherapy could disrupt gut microbiome in patients with breast cancer
Source: The Ohio State Universiy From: medicalxpress.com Chemotherapy is known to cause behavioral side effects, including cognitive decline. Notably, the gut microbiome communicates with the brain to affect behavior, including cognition. “For the first time ever, our Intelligut Study found that the gut microbiome has been implicated in cognitive side effects of chemotherapy in humans,” said senior author Leah Pyter, …
THRIVEOSITY™ LAUNCHES NEW MODEL FOR SUPPORTING CANCER PATIENTS
Start-up Thriveosity™ recently launched its innovative subscription-model box, designed as a gift option for cancer patients, survivors and caregivers to help support them along the path toward becoming thrivers. Thrivers are those who flourish with unbending resilience in the face of adversity. “When someone is diagnosed with cancer, the disruption to daily life is clear—both the illness and the treatments …
Faces of Huntington’s Disease Campaign Highlights
Faces of Huntington’s Disease Campaign Highlights Personal Struggles of Rare Disease Campaign Marks May as Huntington’s Disease Awareness Month and Emphasizes Scientific Hope New York, NY, May 1, 2013 – May is Huntington’s Disease Awareness Month, and the Huntington’s Disease Society of America (HDSA) has launched the Faces of Huntington’s Disease campaign to present a different story of courage and …